EU/3/10/782
Table of contents
About
On 20 September 2010, orphan designation (EU/3/10/782) was granted by the European Commission to Mucokinetica Ltd, United Kingdom, for nafamostat mesilate for the treatment of cystic fibrosis.
Key facts
Active substance |
Nafamostat mesilate
|
Disease / condition |
Treatment of cystic fibrosis
|
Date of first decision |
20/09/2010
|
Outcome |
Positive
|
EU designation number |
EU/3/10/782
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Mucokinetica Ltd
53 Cavendish Road
London SW12 0BL
United Kingdom
Telephone: +44 7774 12 1180
Telefax: +44 20 8673 2266
enquiries@mucokinetica.com
53 Cavendish Road
London SW12 0BL
United Kingdom
Telephone: +44 7774 12 1180
Telefax: +44 20 8673 2266
enquiries@mucokinetica.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.